NYXH
Strong SellSinkerNyxoah SA · Healthcare · Belgium · $163M · Avg Vol: $593K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT NYXOAH SA
Read
Nyxoah SA is a medical technology company developing and commercializing a next-generation hypoglossal nerve stimulation therapy for patients with moderate to severe obstructive sleep apnea (OSA). Its Genio® system offers a unique, battery-free, and leadless implantable solution, aiming to differentiate itself in the sleep apnea treatment market. Nyxoah is a growth-stage medtech company focused on an underserved market, with CE mark approval in Europe and ongoing U.S. clinical trials.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.9M | 3.5M | 5.0M | 5.2M | 11.5M | 91.7% | 24.9M | — | — | — |
| EPS | -1.16 | -0.36 | -0.51 | -0.78 | -1.17 | — | -2.53 | -1.45 | -0.84 | — |
| Shares | 25.8M | 100.1M | 100.1M | 100.1M | 100.1M | +288.3% | 101.8M | — | — | — |
| Debt | 11.7M | 13.7M | 14.6M | 26.0M | 46.5M | 41.3% | 68.9M | — | — | — |
| Equity | 148.6M | 138.3M | 112.6M | 130.1M | 56.5M | -21.5% | — | — | — | — |
| Op CF | -25.3M | -33.0M | -51.5M | -56.6M | -79.3M | — | -82.5M | — | — | — |
| Inv CF | -11.8M | -103.4M | 36.8M | -18.8M | 32.6M | — | — | — | — | — |
| Fin CF | 76.5M | -1.1M | 19.4M | 89.0M | 43.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NYXH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NYXH | Nyxoah SA(you) | $163M | 10 | Strong Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
Peer medians: ROE 16.7% · P/E 18.4x · Gross margin 65.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.